DGIdb - OPRD1 Gene Record

OPRD1 4985 Druggable Genome

Alternate Names:

4985
OPIOID RECEPTOR DELTA 1
OPRD1
OPRD
165195
8153
ENSG00000116329
OTTHUMG00000003646
P41143
OPRD_HUMAN
D-OR-1
Delta-type opioid receptor
DOR-1
DELTA-TYPE OPIOID RECEPTOR (DOR-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P41143]
PA31942
Opioid receptor delta
T58992
DOP
DOR
DOR1

Gene Info:

Human Readable Name	G PROTEIN COUPLED RECEPTOR
Transmembrane Helix Count	7
Target Main Class	Receptors
Target Subclass	Rhodopsin
Target Subclass	GPCR
Human Readable Name	DRUGGABLE GENOME
Interpro Acc	IPR000276
Interpro Short Name	7TM_GPCR_Rhodpsn
Uniprot Evidence	1: Evidence at protein level
Interpro Name	GPCR, rhodopsin-like, 7TM
Interpro Type	Family
Uniprot Status	Swiss-Prot
Target Class	Receptors
Gene Biotype	PROTEIN_CODING

(8 More Sources)

Gene Categories: Category Details

G PROTEIN COUPLED RECEPTOR
DRUGGABLE GENOME

Publications:

Hartvig et al., 1989, Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species., Pharmacol. Toxicol.
Hennies et al., 1988, Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids., Arzneimittelforschung
Guay, 2007, Use of oral oxymorphone in the elderly., Consult Pharm
Fang et al., 1997, 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands., J. Med. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Jiang et al., 1994, 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists., J. Pharmacol. Exp. Ther.
Vandormael B et al., 2011, Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties., J Med Chem
Loghin et al., Influence of glutethimide on rat brain mononucleotides by sub-chronic codeine treatment., J. Cell. Mol. Med.
Advenier et al., 1993, Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist., Eur. J. Pharmacol.
Mignat et al., 1995, Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes., Life Sci.
Ortiz et al., 2005, Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine., Pharmacol. Biochem. Behav.
Karlsson et al., 1990, Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs., J. Pharmacol. Exp. Ther.
Schmidt H et al., 2002, Affinities of dihydrocodeine and its metabolites to opioid receptors., Pharmacol Toxicol
Ashenhurst JR et al., 2012, Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol., Pharmacol Biochem Behav
Herz, 1998, Opioid reward mechanisms: a key role in drug abuse?, Can. J. Physiol. Pharmacol.
Barrios de Tomasi et al., [Opioid antagonists and alcohol consumption]., Rev Neurol
Herz, 1997, Endogenous opioid systems and alcohol addiction., Psychopharmacology (Berl.)
Weerts et al., 2008, Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects., Neuropsychopharmacology
Roy et al., 2005, In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance., J. Neurosci.
Galeotti et al., 2006, Signaling pathway of morphine induced acute thermal hyperalgesia in mice., Pain
Dortch-Carnes et al., 2006, Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide., Pharmacology
Yamada et al., 2006, Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors., Brain Res.
Kieffer et al., 2002, Exploring the opioid system by gene knockout., Prog. Neurobiol.
Asensio et al., 2006, Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal., Eur. J. Pharmacol.
Koch et al., 2006, Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors., J. Neurochem.
Thompson et al., 2004, Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors., J. Pharmacol. Exp. Ther.
Peckham et al., 2006, Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats., J. Pharmacol. Exp. Ther.
Olson KM et al., 2019, Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids., PLoS One
Peng Y et al., 2009, Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways., Bioorg Med Chem
Neil, 1984, Affinities of some common opioid analgesics towards four binding sites in mouse brain., Naunyn Schmiedebergs Arch. Pharmacol.
Gross et al., 2009, Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion., Anesth. Analg.
Fang CP et al., 2020, Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence., J Hum Genet
Eap CB et al., 2002, Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence., Clin Pharmacokinet
Giagnoni et al., 1983, Loperamide: evidence of interaction with mu and delta opioid receptors., Life Sci.
di Bosco et al., 2008, Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors., Chem Biol Drug Des
Barry et al., 2005, Opioids: old drugs for potential new applications., Curr. Pharm. Des.
Mayberg et al., 1991, Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography., Ann. Neurol.
De Souza et al., 1988, Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic., J. Pharmacol. Exp. Ther.
Chen et al., 1993, The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine., Life Sci.
Fujita et al., 2014, Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers., Biochem. Pharmacol.
Breslin et al., 2012, Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)., Bioorg. Med. Chem. Lett.
Ingman K et al., 2005, Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing., Neuropsychopharmacology
Paille F et al., 2014, Nalmefene: a new approach to the treatment of alcohol dependence., Subst Abuse Rehabil
Sahin et al., 2005, The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro., J. Cardiothorac. Vasc. Anesth.
Poonawala et al., Opioids heal ischemic wounds in the rat., Wound Repair Regen
Rodrigues et al., 2005, Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats., Braz. J. Med. Biol. Res.
Darwish et al., 2006, Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers., Clin Ther
Hajiha et al., 2009, Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo., J. Physiol. (Lond.)
Darwish et al., 2005, Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers., Clin Pharmacokinet
Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
Crist RC et al., 2019, Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder., Pharmacogenomics J
Clarke TK et al., 2014, Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females., Pharmacogenomics J
Crist RC et al., 2013, An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans., Neuropsychopharmacology
Lester et al., 2006, Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes., Brain Res.
Induru et al., Buprenorphine for neuropathic pain--targeting hyperalgesia., Am J Hosp Palliat Care
Mégarbane et al., 2006, Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation., Toxicol. Appl. Pharmacol.
Fan et al., 2002, Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain., Brain Res. Bull.
Picker et al., 1996, Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists., J. Pharmacol. Exp. Ther.
Fan et al., 2002, Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding., Brain Res.
Walsh et al., 2008, Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade., Psychopharmacology (Berl.)
Narita et al., 1994, Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain., Eur. J. Pharmacol.
Commiskey et al., 2005, Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors., J. Pharmacol. Sci.
Wakabayashi et al., 1995, Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine., Neurochem. Res.
Cai J et al., 2014, Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity., Bioorg Med Chem
Kakinohana et al., 2003, Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study., Anesthesiology
Helm et al., Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification., Pain Physician
Moncada et al., 2003, Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice., Eur. J. Pharmacol.
Breljak et al., Oligopeptide fragments of the enkephalin molecule interfere with hematopoietic cell colony formation., Int J Immunopathol Pharmacol
Osman et al., 2003, A possible role for an enkephalinergic system in the internal defense mechanism of Biomphalaria alexandrina exposed to Schistosoma mansoni., J Egypt Soc Parasitol
Chudapongse et al., 2003, Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells., J. Pharmacol. Sci.
van Dorp et al., 2007, Naloxone treatment in opioid addiction: the risks and benefits., Expert Opin Drug Saf
Wentland et al., 2009, Syntheses and opioid receptor binding properties of carboxamido-substituted opioids., Bioorg. Med. Chem. Lett.
Barakat A, 2019, Revisiting Tramadol: A Multi-Modal Agent for Pain Management., CNS Drugs
Ordóñez Gallego et al., 2007, Oxycodone: a pharmacological and clinical review., Clin Transl Oncol
Ananthan et al., 2004, Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]., J. Med. Chem.
Chamberlin et al., 2007, Oral oxymorphone for pain management., Ann Pharmacother
Freye et al., 1992, The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects., Eur J Anaesthesiol
Zhu et al., 1996, The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor., FEBS Lett.

ELUXADOLINE OPRD1

Interaction Score: 3.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
25261794 22695132

Sources:
DTC TTD
HYDROMORPHONE OPRD1

Interaction Score: 2.71

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Trial Name NMED-1077,Exalgo, Jurnista, Dilaudid

Novel drug target Established target

PMIDs:
2478994 2849950 17658959 9301669 11752352 7511163

Sources:
TdgClinicalTrial TEND TTD
BUTORPHANOL OPRD1

Interaction Score: 2.37

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12127012 8968334 12470863 17909753 7705457 15942128 11752352 8746803

Sources:
TdgClinicalTrial TEND TTD
CARFENTANIL OPRD1

Interaction Score: 2.26

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
15853689 1656846

Sources:
TTD
NALTREXONE OPRD1

Interaction Score: 2.07

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
CODEINE OPRD1

Interaction Score: 1.89

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12067475 8119316 7885194 16386786 11752352 2156065 12420793

Sources:
TdgClinicalTrial TEND TTD
HYDROCODONE OPRD1

Interaction Score: 1.81

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ZX002, hydrocodone bitartrate

Novel drug target Established target

Trial Name PTI-701

PMIDs:
14600248 11752352 16291875 31170174

Sources:
TdgClinicalTrial TEND
ADL-5747 OPRD1

Interaction Score: 1.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NALOXONE OPRD1

Interaction Score: 1.51

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name REN-213

Novel drug target Established target

PMIDs:
24613457 12657847 18354714 12650833 12749773 14708857 14646257 17367258

Sources:
DTC TdgClinicalTrial TEND
NALMEFENE OPRD1

Interaction Score: 1.51

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name nalmefene, CPH-101

Novel drug target Established target

PMIDs:
15956985 25187751

Sources:
TdgClinicalTrial
ADL-5747 OPRD1

Interaction Score: 1.51

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ADL5747

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
CHEMBL409225 OPRD1

Interaction Score: 1.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21978284

Sources:
DTC
BUPRENORPHINE OPRD1

Interaction Score: 1.36

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name V1003

Novel drug target Established target

Trial Name ALKS 5461

PMIDs:
30549211 30368523 24126707 23612435 16443205 19666890 16169027

Sources:
TdgClinicalTrial PharmGKB
NALBUPHINE OPRD1

Interaction Score: 1.26

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name nalbuphine hydrochloride, PW-4142

Novel drug target Established target

Trial Name REN-213

PMIDs:
2826773 8093631 11752352

Sources:
TdgClinicalTrial TEND
OXYMORPHONE OPRD1

Interaction Score: 1.13

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name oxymorphone hydrochloride, EN3202,Opana, Opana ER

Novel drug target Established target

PMIDs:
14998329 17595308

Sources:
TdgClinicalTrial
PROPOXYPHENE OPRD1

Interaction Score: 1.13

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
6151117

Sources:
TdgClinicalTrial TEND
OXYCODONE OPRD1

Interaction Score: 1.01

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name COL-003, sustained release oxycodone

Novel drug target Established target

Trial Name COL-172, extended-release oxycodone

PMIDs:
17525040 11752352

Sources:
TdgClinicalTrial TEND PharmGKB TTD
SNC-80 OPRD1

Interaction Score: 1.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19646882

Sources:
DTC
CHEMBL300662 OPRD1

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CHEMBL13786 OPRD1

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SUFENTANIL OPRD1

Interaction Score: 0.65

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name sufentanil transdermal patch,Transdur-sufentanil

Novel drug target Established target

Trial Name sufentanil,Chronogesic

PMIDs:
1330549 8612823

Sources:
TdgClinicalTrial
FENTANYL OPRD1

Interaction Score: 0.6

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name transmucosal fentanyl,Actiq

Trial Name fentanyl transdermal system,Duragesic, Ionsys

Trial Name fentanyl sublingual spray

PMIDs:
15868528 15828941 15665994 16861092 19403616 16372825 30549211

Sources:
TdgClinicalTrial TEND PharmGKB
LOPERAMIDE OPRD1

Interaction Score: 0.6

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
6319884 18284554 11752352

Sources:
TTD
NALTREXONE HYDROCHLORIDE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
NALBUPHINE HYDROCHLORIDE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CODEINE POLISTIREX OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
HYDROCODONE POLISTIREX OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
HYDROCODONE BITARTRATE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CODEINE SULFATE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CODEINE PHOSPHATE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

PMIDs:
None found

Sources:
ChemblInteractions
NALMEFENE HYDROCHLORIDE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

PMIDs:
None found

Sources:
ChemblInteractions
ODELEPRAN OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
OXYMORPHONE HYDROCHLORIDE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

PMIDs:
None found

Sources:
ChemblInteractions
BENZHYDROCODONE HYDROCHLORIDE OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name KP201 (prodrug of hydrocodone)

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
AXOMADOL OPRD1

Interaction Score: 0.5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Delta opioid receptor agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
MORPHINE OPRD1

Interaction Score: 0.44

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

Novel drug target Established target

Trial Name intranasal morphine,Rylomine

PMIDs:
16650582 16534251 16530171 12015197 16678156 11752352 16539674

Sources:
TdgClinicalTrial TEND
CEBRANOPADOL OPRD1

Interaction Score: 0.38

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Opioid receptors; mu/kappa/delta agonist

PMIDs:
None found

Sources:
ChemblInteractions
NALOXONE HYDROCHLORIDE OPRD1

Interaction Score: 0.38

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TRAMADOL OPRD1

Interaction Score: 0.34

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
19027293 30549211 31004280

Sources:
PharmGKB
METHADONE OPRD1

Interaction Score: 0.22

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
19843777 31907389 12405865

Sources:
PharmGKB
COCAINE OPRD1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000116329
- Version: 101_38
Alternate Names:

OPRD1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
RussLampel: ENSG00000116329
- Version: 26-July-2011
Alternate Names:

OPRD1 Display Id

ENSG00000116329 Ensembl Gene Id

DELTA-TYPE OPIOID RECEPTOR (DOR-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P41143] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
TEND: P41143
- Version: 01-August-2011
Alternate Names:

P41143 Uniprot Accession

OPRD_HUMAN Uniprot Id

4985 Entrez Gene Id

Gene Info:

Transmembrane Helix Count 7

Target Main Class Receptors

Target Subclass Rhodopsin

Publications:
HopkinsGroom: P41143
- Version: 11-September-2012
Alternate Names:

DELTA-TYPE OPIOID RECEPTOR Uniprot Protein Name

OPRD1 Uniprot Gene Name

P41143 Uniprot Accession

Gene Info:

Human Readable Name DRUGGABLE GENOME

Interpro Acc IPR000276

Interpro Short Name 7TM_GPCR_Rhodpsn

Gene Categories:

G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

Publications:
TdgClinicalTrial: P41143
- Version: January-2014
Alternate Names:

OPRD1 Gene Symbol

Gene Info:

Target Subclass Rhodopsin

Target Class Receptors

Target Subclass GPCR

Publications:

PharmGKB: OPRD1

Version: 18-August-2020

Alternate Names:

PA31942 PharmGKB ID

Gene Info:

Publications:

Fang CP et al., 2020, Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence., J Hum Genet

Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol

Crist RC et al., 2013, An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans., Neuropsychopharmacology

TTD: Opioid receptor delta
- Version: 2020.06.01
Alternate Names:

OPRD1 TTD Gene Abbreviation

T58992 TTD Target ID

Gene Info:

Publications:

Al-Hasani R et al., 2011, Molecular mechanisms of opioid receptor-dependent signaling and behavior., Anesthesiology

DTC: OPRD1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Vandormael B et al., 2011, Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties., J Med Chem

Cai J et al., 2014, Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity., Bioorg Med Chem

Breslin et al., 2012, Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)., Bioorg. Med. Chem. Lett.

ChemblInteractions: OPRD
- Version: chembl_23
Alternate Names:

OPRD GENE_SYMBOL

OPRD1 GENE_SYMBOL

Delta-type opioid receptor UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000116329
- Version: 31-May-2017
Alternate Names:

ENSG00000116329 Gene Symbol

OPRD1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: OPRD1
- Version: 01-February-2022
Alternate Names:

OPRD GO Gene Synonym

Gene Info:

Gene Categories:

G PROTEIN COUPLED RECEPTOR

Publications:
dGene: OPRD1
- Version: 27-Jun-2013
Alternate Names:

4985 Gene ID

OPRD dGene Synonym

Gene Info:

Gene Categories:

G PROTEIN COUPLED RECEPTOR

Publications:

Trial Name	NMED-1077,Exalgo, Jurnista, Dilaudid
Novel drug target	Established target

Mechanism of Interaction	Opioid receptors; mu/kappa/delta antagonist
Direct Interaction	yes
Trial Name	ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

Trial Name	ZX002, hydrocodone bitartrate
Novel drug target	Established target
Trial Name	PTI-701

Trial Name	nalmefene, CPH-101
Novel drug target	Established target

Trial Name	V1003
Novel drug target	Established target
Trial Name	ALKS 5461

Trial Name	nalbuphine hydrochloride, PW-4142
Novel drug target	Established target
Trial Name	REN-213

Trial Name	oxymorphone hydrochloride, EN3202,Opana, Opana ER
Novel drug target	Established target

Trial Name	COL-003, sustained release oxycodone
Novel drug target	Established target
Trial Name	COL-172, extended-release oxycodone

Trial Name	sufentanil transdermal patch,Transdur-sufentanil
Novel drug target	Established target
Trial Name	sufentanil,Chronogesic

Trial Name	transmucosal fentanyl,Actiq
Trial Name	fentanyl transdermal system,Duragesic, Ionsys
Trial Name	fentanyl sublingual spray

agonist (activating)
antagonist (inhibitory)

agonist (activating)
antagonist (inhibitory)

Mechanism of Interaction	Opioid receptors; mu/kappa/delta agonist
Direct Interaction	yes

Trial Name	KP201 (prodrug of hydrocodone)
Novel drug target	Established target

Mechanism of Interaction	Delta opioid receptor agonist
Direct Interaction	yes

OPRD1	Display Id
ENSG00000116329	Ensembl Gene Id
DELTA-TYPE OPIOID RECEPTOR (DOR-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P41143]	Description

P41143	Uniprot Accession
OPRD_HUMAN	Uniprot Id
4985	Entrez Gene Id

DELTA-TYPE OPIOID RECEPTOR	Uniprot Protein Name
OPRD1	Uniprot Gene Name
P41143	Uniprot Accession

OPRD	GENE_SYMBOL
OPRD1	GENE_SYMBOL
Delta-type opioid receptor	UNIPROT

OPRD1 Gene Record

OPRD1 4985 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 25261794 22695132

Sources: DTC TTD

Interaction Types & Directionality: partial agonist (activating) agonist (activating)

Interaction Info: Trial Name NMED-1077,Exalgo, Jurnista, Dilaudid Novel drug target Established target

PMIDs: 2478994 2849950 17658959 9301669 11752352 7511163

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12127012 8968334 12470863 17909753 7705457 15942128 11752352 8746803

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 15853689 1656846

Sources: TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist Direct Interaction yes Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs: 22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12067475 8119316 7885194 16386786 11752352 2156065 12420793

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name ZX002, hydrocodone bitartrate Novel drug target Established target Trial Name PTI-701

PMIDs: 14600248 11752352 16291875 31170174

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name REN-213 Novel drug target Established target

PMIDs: 24613457 12657847 18354714 12650833 12749773 14708857 14646257 17367258

Sources: DTC TdgClinicalTrial TEND

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name nalmefene, CPH-101 Novel drug target Established target

PMIDs: 15956985 25187751

Sources: TdgClinicalTrial

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name ADL5747 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21978284

Sources: DTC

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name V1003 Novel drug target Established target Trial Name ALKS 5461

PMIDs: 30549211 30368523 24126707 23612435 16443205 19666890 16169027

Sources: TdgClinicalTrial PharmGKB

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name nalbuphine hydrochloride, PW-4142 Novel drug target Established target Trial Name REN-213

PMIDs: 2826773 8093631 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name oxymorphone hydrochloride, EN3202,Opana, Opana ER Novel drug target Established target

PMIDs: 14998329 17595308

Sources: TdgClinicalTrial

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 6151117

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name COL-003, sustained release oxycodone Novel drug target Established target Trial Name COL-172, extended-release oxycodone

PMIDs: 17525040 11752352

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19646882

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
25261794 22695132

Sources:
DTC TTD

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Trial Name NMED-1077,Exalgo, Jurnista, Dilaudid

Novel drug target Established target

PMIDs:
2478994 2849950 17658959 9301669 11752352 7511163

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12127012 8968334 12470863 17909753 7705457 15942128 11752352 8746803

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

agonist (activating)

PMIDs:
15853689 1656846

Sources:
TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Opioid receptors; mu/kappa/delta antagonist

Direct Interaction yes

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
22954510 9673788 17661275 9040115 17487229 11752352 15788780

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12067475 8119316 7885194 16386786 11752352 2156065 12420793

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ZX002, hydrocodone bitartrate

Novel drug target Established target

Trial Name PTI-701

PMIDs:
14600248 11752352 16291875 31170174

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name REN-213

Novel drug target Established target

PMIDs:
24613457 12657847 18354714 12650833 12749773 14708857 14646257 17367258

Sources:
DTC TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name nalmefene, CPH-101

Novel drug target Established target

PMIDs:
15956985 25187751

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ADL5747

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
21978284

Sources:
DTC

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name V1003

Novel drug target Established target

Trial Name ALKS 5461

PMIDs:
30549211 30368523 24126707 23612435 16443205 19666890 16169027

Sources:
TdgClinicalTrial PharmGKB

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name nalbuphine hydrochloride, PW-4142

Novel drug target Established target

Trial Name REN-213

PMIDs:
2826773 8093631 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name oxymorphone hydrochloride, EN3202,Opana, Opana ER

Novel drug target Established target

PMIDs:
14998329 17595308

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
6151117

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name COL-003, sustained release oxycodone

Novel drug target Established target

Trial Name COL-172, extended-release oxycodone

PMIDs:
17525040 11752352

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
19646882

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name sufentanil transdermal patch,Transdur-sufentanil

Novel drug target Established target

Trial Name sufentanil,Chronogesic

PMIDs:
1330549 8612823

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name transmucosal fentanyl,Actiq

Trial Name fentanyl transdermal system,Duragesic, Ionsys

Trial Name fentanyl sublingual spray

PMIDs:
15868528 15828941 15665994 16861092 19403616 16372825 30549211